CorMedix Therapeutics announced it holds approximately $355 million in cash as of September 30, 2026, and reaffirmed its full-year 2026 revenue guidance of $325-$345 million. The company highlighted the CMS 2027 End-Stage Renal Disease payment rule, which sets a higher add-on payment for its DefenCath product at $8.32 per dialysis session in Q1 2027, significantly above the current $2.37 rate. CorMedix expects fluctuations in the add-on rate throughout 2027 but anticipates the average will be more than double the current rate. A conference call is scheduled for November 12, 2026, to discuss detailed financial results and updates.
CorMedix Therapeutics' recent business update provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US health-sector stocks, 82 rose and 47 fell today. Notable movers include IDEXX Laboratories, Inc. (IDXX) at USD 585.99 with a 6.31% increase and a typical hold time of 47 days, Cassava Sciences Inc (FLNA) at USD 0.66 up 6.11% with a 39-day hold, and Ginkgo Bioworks Holdings Inc (DNA) at USD 11.79 rising 4.99% with a 9-day hold time.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Tigo Energy, Fluence Energy, and Anavex Life Sciences. The lawsuits allege these companies made false or misleading stat...
Heineken N.V. has repurchased a total of 9,510,681 shares under the second tranche of its €1.5 billion share buyback program, spending €679.2 million as of October 30, 2026. The company bought 159,700 shares on the exchange and 160,530 shares from He...
Alvotech, a global biotech company specializing in biosimilars, announced its management team will participate in several investor conferences in November 2026, including events in London, Oslo, and Stockholm. These presentations and fireside chats w...
Alvotech, a global biotech company specializing in biosimilar medicines, announced its management team will participate in several investor conferences throughout November 2026. These include events in London, Oslo, and Stockholm, featuring presentat...
Alvotech, a global biotechnology company specializing in biosimilar medicines, will participate in four international investor conferences in November held in the UK, Norway, and Sweden. These events include presentations and analyst discussions host...
